ADPT
Adaptive Biotechnologies Corp

4,306
Mkt Cap
$2.51B
Volume
1.11M
52W High
$20.76
52W Low
$6.26
PE Ratio
-41.28
ADPT Fundamentals
Price
$16.01
Prev Close
$16.46
Open
$16.22
50D MA
$16.87
Beta
1.71
Avg. Volume
1.96M
EPS (Annual)
-$0.3922
P/B
11.57
Rev/Employee
$447,457.19
$2,453.55
Loading...
Loading...
News
all
press releases
Jupiter Asset Management Ltd. Acquires 221,158 Shares of Adaptive Biotechnologies Corporation $ADPT
Jupiter Asset Management Ltd. grew its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) by 442.6% during the 3rd quarter, according to its most recent Form 13F...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Affinity Wealth Management LLC Buys Shares of 303,533 Adaptive Biotechnologies Corporation $ADPT
Affinity Wealth Management LLC purchased a new position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) in the third quarter, according to its most recent disclosure...
MarketBeat·14d ago
News Placeholder
Principal Financial Group Inc. Sells 303,285 Shares of Adaptive Biotechnologies Corporation $ADPT
Principal Financial Group Inc. lessened its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) by 33.3% during the 3rd quarter, according to its most recent 13F...
MarketBeat·14d ago
News Placeholder
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) by 305.8% in the third quarter, according to the company in its most...
MarketBeat·17d ago
News Placeholder
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen raised shares of Adaptive Biotechnologies from a "hold" rating to a "buy" rating in a report on Sunday...
MarketBeat·20d ago
News Placeholder
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 2,145 shares of the stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an...
MarketBeat·21d ago
News Placeholder
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00
JPMorgan Chase & Co. boosted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Friday...
MarketBeat·21d ago
News Placeholder
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Better-Than-Expected Earnings
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up After Strong Earnings...
MarketBeat·21d ago
News Placeholder
Adaptive Biotechnologies Q4 Earnings Call Highlights
Adaptive Biotechnologies (NASDAQ:ADPT) executives said the company delivered remarkable performance in 2025, driven by sharp growth and improving profitability in its minimal residual disease (MRD...
MarketBeat·22d ago
News Placeholder
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·22d ago
<
1
2
...
>

Latest ADPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.